Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice
Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice作者机构:CAS Key Laboratory of Molecular Virology&ImmunologyInstitut Pasteur of ShanghaiChinese Academy of SciencesShanghai200031China State Key Laboratory of VirologyChinese Academy of SciencesWuhan430071China University of Chinese Academy of SciencesBeijing100049China Center for Biosafety Mega-ScienceWuhan Institute of VirologyChinese Academy of SciencesWuhan430071China
出 版 物:《Virologica Sinica》 (中国病毒学(英文版))
年 卷 期:2022年第37卷第4期
页 面:581-590页
核心收录:
学科分类:1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学]
基 金:the National Natural Science Foundation of China(No.32070933 to J.M.Lan and Y.F.Yao) the Natural Science Foundation of Shanghai(No.20ZR1463900 to J.M.Lan) financially the STS regional key project(KFJ-STS-QYZD-2021-12-001 to Z.M.Yuan and C.Shan)from Chinese Academy of Sciences National Key R&D Program of China 2021YFE0201900 to C.Shan and 2021YFC0863300 to Z.M.Yuan and C.Shan the National Key R&D Program of China(No.2021YFC0863400) funding from Institut Pasteur,Fondation Merieux and the Chinese Academy of Sciences to G.W
主 题:SARS-CoV-2 Vaccine Chimpanzee adenovirus vector Neutralizing antibodies Long-term protection
摘 要:SARS-CoV-2 infection is a global public health *** are considered amongst the most important tools to control the SARS-CoV-2 *** expected,deaths from SARS-CoV-2 infection have dropped dramatically with widespread ***,there are concerns over the duration of vaccine-induced protection,as well as their effectiveness against emerging variants of ***,we constructed a recombinant chimpanzee adenovirus vectored vaccine expressing the full-length spike of SARS-CoV-2(Ad C68-S).Rapid and high levels of humoral and cellular immune responses were observed after immunization of C57BL/6J mice with one or two doses of Ad ***,neutralizing antibodies were observed up to at least six months after vaccination,without substantial *** or double doses Ad C68-S immunization resulted in lower viral loads in lungs of mice against SARS-CoV-2 challenge both in the short term(21 days)and long-term(6 months).Histopathological examination of Ad C68-S immunized mice lungs showed mild histological abnormalities after SARS-CoV-2 *** together,this study demonstrates the efficacy and durability of the Ad C68-S vaccine and constitutes a promising candidate for clinical evaluation.